Baxter Has New Research on 3-in-1 Oxiris Set for CRRT and Sepsis Management

• Blood Purification supplement includes studies on real-world use of Oxiris to treat patients in the intensive care unit (ICU)
• Studies add to scientific exchange on the role of blood filtering technology to address critical conditions
• Patient registry is being started to generate additional evidence on Oxiris

Baxter International Inc. (NYSE: BAX), a global leader in acute care therapies, announced today that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis. The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy this week, add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions.

https://www.businesswire.com/news/home/20190528005334/en/Baxter-Announces-New-Research-3-in-1-Oxiris-Set